CClinicalTrials.gg
Not yet recruitingNCT07062081Updated Jul 14, 2025

Correlation Between Acne Vulgaris and Lipid Profile Among Young Adults in Sohag Governorate

An interventional study of lipid profile in Acne Vulgaris, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 12 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Sohag University · Not applicable, Interventional, and Screening

From the registry’s dates

  • Primary completion was expected by Jan 2026, 8 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
12 Years to 45 Years
Sex
All
01

Study summary

Acne vulgaris is the most common skin condition affecting late adolescents worldwide.1 The prevalence of acne is said to be 85% in adults aged 12 to 25 years.2 Almost all teenagers between 15 and 17 years report having some degree of acne.3 Estimates of the lifetime occurrence of acne in the literature range from 0.1%4 to as high as 85.1%5 in the general population, depending on the age range, region, and method of sampling. Overall, acne is more common in women,8,9 but in some literature the prevalence is approximately equal in men and women.10,11

Read the detailed description

Acne vulgaris is a multifactorial disorder of the pilosebaceous unit, resulting from sebum overproduction, follicular hyperkeratinization, inflammation, and bacterial colonization of hair follicles by Propionibacterium acnes. The sebaceous gland is controlled primarily by hormonal stimulation. In this way, the hormonal effect on sebum secretion is a key to the pathogenesis of acne.12-16 During puberty, alteration of the sebum component, called dysseborrhea, stress, irritation, cosmetics, and potential dietary factors lead to the formation of acne lesions.16 Changes in sebum secretion are considered to be an important factor of acne. In this way, increased sebum secretion can induce acne occurrence.17 Increasing evidence, in essence, indicates that changes in lipid profile are strongly related to acne occurrence. Accordingly, further information and awareness campaigns are needed to emphasize the role of balanced lipid metabolism to control acne. Although a correlation between the incidence of acne and lipid profile levels has been observed before, it must be documented in each population with etiological characteristics. Minimal reports are available on the relationship between plasma lipids and acne in our country. Hence, we aim to establish this study to estimate the presence of lipid alteration in acne patients.

02

Conditions studied

  • Acne Vulgaris

Browse trials for

03

In context

Acne Vulgaris

730 studies on the registry are indexed under Acne Vulgaris; 86 are open to participants now.

This study's planned enrollment of 100 is above the median of 69 across 628 interventional studies indexed under Acne Vulgaris.

Browse Acne Vulgaris studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • age- and sex-matched healthy volunteers, not taking any medicine, and having no personal or family history of acne.

Exclusion criteria

Exclusion Criteria:

  • : reluctance to take part in the study, pregnancy or lactation

    • intake of oral contraception or hormone therapy, history of taking any medications that affect lipid metabolism or oral isotretinoin
    • and systemic diseases that affect the metabolism of lipids, such as uncontrolled diabetes, hypothyroidism, nephrotic syndrome, end-stage renal failure, HIV, familial hypercholesterolemia, and metabolic syndrome.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Interventions

  • Diagnostic testlipid profile

    The blood samples were taken to measure lipid profile levels as triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) and VLDL values.

06

What researchers measure

Primary outcomes

  1. lipid profile (TG)

    The blood samples were taken to measure lipid profile levels as triglycerides (TG)

    Time frame: 6 months

  2. lipid profile (HDL)

    The blood samples were taken to measure lipid profile levels as HDL

    Time frame: 6 months

  3. lipid profile (VLDL)

    The blood samples were taken to measure lipid profile levels as VLDL

    Time frame: 6 months

07

Study locations

1 site
  • Sohag university Hospital
    Sohag, Egypt
    • Magdy M Amin, professor · Contact
08

References and documents

Publications

  • Degitz K, Ochsendorf F. Pharmacotherapy of acne. Expert Opin Pharmacother. 2008 Apr;9(6):955-71. doi: 10.1517/14656566.9.6.955. PubMed 18377339 ↗
  • Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996 Sep;35(9):633-9. doi: 10.1111/j.1365-4362.1996.tb03687.x. PubMed 8876289 ↗
  • Dreno B. Treatment of adult female acne: a new challenge. J Eur Acad Dermatol Venereol. 2015 Jun;29 Suppl 5:14-9. doi: 10.1111/jdv.13188. PubMed 26059821 ↗
  • Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, Elewski BE. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008 Jan;58(1):56-9. doi: 10.1016/j.jaad.2007.06.045. Epub 2007 Oct 22. PubMed 17945383 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07062081
Lead sponsor
Sohag University
Responsible party
Hager Ali Dardier (demonostrator at family medicine department, Sohag University) — Principal investigator
First posted
Jul 14, 2025
Start date
Aug 1, 2025 (estimated)
Primary completion
Jan 30, 2026 (estimated)
Completion
Jan 30, 2026 (estimated)
Last update
Jul 14, 2025

Study contacts

Hager A dardier, demonastrator
Contact
hager.dardir@med.sohag.edu.eg
01129977680
hanan A metwaly, professor
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion